147 related articles for article (PubMed ID: 2075758)
21. Experimental infections with wild and mutant Yersinia pseudotuberculosis strains in rabbits.
Najdenski H; Vesselinova A; Golkocheva E; Garbom S; Wolf-Watz H
J Vet Med B Infect Dis Vet Public Health; 2003 Aug; 50(6):280-8. PubMed ID: 14628999
[TBL] [Abstract][Full Text] [Related]
22. Studies on aerosol Yersinia pseudotuberculosis infection of guinea-pigs.
Velianov D; Nikolova S; Naĭdenski Kh; Raducheva T; Kŭsovski V; Grigoriev I; Ilieva L
Acta Microbiol Bulg; 1993; 30():3-10. PubMed ID: 8285130
[TBL] [Abstract][Full Text] [Related]
23. [Chemotaxis of Yersinia pseudotuberculosis as a mechanism in its search for target tissues of the host organism].
Venediktov VS; Timchenko NF; Antonenko FF; Stepanenko VI
Zh Mikrobiol Epidemiol Immunobiol; 1988 May; (5):77-81. PubMed ID: 3046198
[TBL] [Abstract][Full Text] [Related]
24. [Microbiology and epidemiology of Yersinia infections].
Aleksić S; Bockemühl J
Immun Infekt; 1990 Dec; 18(6):178-85. PubMed ID: 2076900
[TBL] [Abstract][Full Text] [Related]
25. The serodiagnosis of human infections with Yersinia enterocolitica and Yersinia pseudotuberculosis.
Chart H; Cheasty T
FEMS Immunol Med Microbiol; 2006 Aug; 47(3):391-7. PubMed ID: 16872375
[TBL] [Abstract][Full Text] [Related]
26. The invasin D protein from
Sadana P; Geyer R; Pezoldt J; Helmsing S; Huehn J; Hust M; Dersch P; Scrima A
J Biol Chem; 2018 Jun; 293(22):8672-8690. PubMed ID: 29535184
[No Abstract] [Full Text] [Related]
27. Clinical role for a superantigen in Yersinia pseudotuberculosis infection.
Abe J; Onimaru M; Matsumoto S; Noma S; Baba K; Ito Y; Kohsaka T; Takeda T
J Clin Invest; 1997 Apr; 99(8):1823-30. PubMed ID: 9109426
[TBL] [Abstract][Full Text] [Related]
28. Distribution of virF/lcrF-positive Yersinia pseudotuberculosis serotype O:3 at farm level.
Niskanen T; Laukkanen R; Fredriksson-Ahomaa M; Korkeala H
Zoonoses Public Health; 2008 May; 55(4):214-21. PubMed ID: 18387143
[TBL] [Abstract][Full Text] [Related]
29. [Yersinia L-transformation in experimental pseudotuberculosis].
Isachkova LM; Zhavoronkova AA; Shubin FN
Zh Mikrobiol Epidemiol Immunobiol; 1993; (1):11-6. PubMed ID: 8067064
[TBL] [Abstract][Full Text] [Related]
30. The role of V antigen in mice experimentally infected with Yersinia pseudotuberculosis; histopathological study using enzyme immunoassay.
Sugiyama Y; Kaneko K; Takashima I; Hashimoto N
Nihon Juigaku Zasshi; 1986 Aug; 48(4):781-9. PubMed ID: 3531653
[No Abstract] [Full Text] [Related]
31. A role for Toll-like receptor 4 in the host response to the lung infection of Yersinia pseudotuberculosis in mice.
Choi JA; Jeong YJ; Kim JE; Kang MJ; Kim JC; Oh SM; Lee KB; Kim DH; Kim DJ; Park JH
Comp Immunol Microbiol Infect Dis; 2016 Feb; 44():54-60. PubMed ID: 26851596
[TBL] [Abstract][Full Text] [Related]
32. CD8(+) T cells restrict Yersinia pseudotuberculosis infection: bypass of anti-phagocytosis by targeting antigen-presenting cells.
Bergman MA; Loomis WP; Mecsas J; Starnbach MN; Isberg RR
PLoS Pathog; 2009 Sep; 5(9):e1000573. PubMed ID: 19730693
[TBL] [Abstract][Full Text] [Related]
33. CD8(+) T cells specific to a single Yersinia pseudotuberculosis epitope restrict bacterial replication in the liver but fail to provide sterilizing immunity.
Shen H; Gonzalez-Juarbe N; Blanchette K; Crimmins G; Bergman MA; Isberg RR; Orihuela CJ; Dube PH
Infect Genet Evol; 2016 Sep; 43():289-96. PubMed ID: 27268148
[TBL] [Abstract][Full Text] [Related]
34. [INTESTINAL FAILURE AND YERSINIA PSEUDOTUBERCULOSIS TRANSLOCATION IN THE DEVELOPMENTOF EXPERIMENTAL GENERALIZED INFECTION].
Chicherin IY; Pogorelky IP; Lundovskikh IA; Darmov IV; Gorshkov AS; Shabalina MR
Eksp Klin Gastroenterol; 2016; (3):24-31. PubMed ID: 27301139
[TBL] [Abstract][Full Text] [Related]
35. Ultrastructural Changes of Bacteria in Static Cultures of Yersinia pseudotuberculosis under Long Storage under Conditions of Low Temperature.
Somova LM; Timchenko NF; Lyapun IN; Drobot EI; Matosova EV; Bynina MP
Bull Exp Biol Med; 2020 Dec; 170(2):223-225. PubMed ID: 33263854
[TBL] [Abstract][Full Text] [Related]
36. [The temperature-induced early and late development of resistance to the bactericidal action of blood serum in Yersinia pseudotuberculosis].
Timchenko NF; Venediktov VS; Nedashkovskaia EP; Frolova GM
Zh Mikrobiol Epidemiol Immunobiol; 1992 Jan; (1):2-4. PubMed ID: 1414100
[TBL] [Abstract][Full Text] [Related]
37. Oral inoculation with Type III secretion mutants of Yersinia pseudotuberculosis provides protection from oral, intraperitoneal, or intranasal challenge with virulent Yersinia.
Balada-Llasat JM; Panilaitis B; Kaplan D; Mecsas J
Vaccine; 2007 Feb; 25(8):1526-33. PubMed ID: 17194509
[TBL] [Abstract][Full Text] [Related]
38. [Choice of models for determining the pathogenic properties of the causative agent of pseudotuberculosis].
Tseneva GIa; Polotskiĭ IuE; Kleganov VK; Efremov VE
Zh Mikrobiol Epidemiol Immunobiol; 1982; (11):68-71. PubMed ID: 6760632
[TBL] [Abstract][Full Text] [Related]
39. [Interaction of Yersinia pseudotuberculosis with the epithelium of the small intestine in experimental infection].
Isachkova LM; Zhavoronkov AA; Timchenko NF
Biull Eksp Biol Med; 1985 Jul; 100(7):117-20. PubMed ID: 3893561
[TBL] [Abstract][Full Text] [Related]
40. The role of the phoPQ operon in the pathogenesis of the fully virulent CO92 strain of Yersinia pestis and the IP32953 strain of Yersinia pseudotuberculosis.
Bozue J; Mou S; Moody KL; Cote CK; Trevino S; Fritz D; Worsham P
Microb Pathog; 2011 Jun; 50(6):314-21. PubMed ID: 21320584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
